A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

BACKGROUND: This was a first-in-human Phase 1/2 open-label dose-escalation study of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737. METHODS: Patients with advanced solid tumours enrolled in dose-escalation cohorts and received SRA737 monotherapy orally on a continuous daily (QD) dosing schedu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristeleit, Rebecca, Plummer, Ruth, Jones, Robert, Carter, Louise, Blagden, Sarah, Sarker, Debashis, Arkenau, Tobias, Evans, Thomas R. Jeffry, Danson, Sarah, Symeonides, Stefan N., Veal, Gareth J., Klencke, Barbara J., Kowalski, Mark M., Banerji, Udai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307885/
https://www.ncbi.nlm.nih.gov/pubmed/37120671
http://dx.doi.org/10.1038/s41416-023-02279-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307885/
https://www.ncbi.nlm.nih.gov/pubmed/37120671
http://dx.doi.org/10.1038/s41416-023-02279-x

Ejemplares similares